Cytochromes P450 and cancer.
Kaminsky
L S
LS
Spivack
S D
SD
D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics / Q000378:metabolism; D065633:Cytochrome P-450 CYP1B1; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism*; D020022:Genetic Predisposition to Disease; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D011110:Polymorphism, Genetic; D015262:Xenobiotics / Q000378:metabolism
D000970:Antineoplastic Agents; D015262:Xenobiotics; D003577:Cytochrome P-450 Enzyme System; D019392:Cytochrome P-450 CYP2E1; D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; D019363:Cytochrome P-450 CYP1A1; D065633:Cytochrome P-450 CYP1B1; D019389:Cytochrome P-450 CYP2D6